A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

NCT01548287 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment
Mild Alzheimer's Disease

Interventions

DRUG: AZD5213
DRUG: AZD5213
DRUG: AZD5213
OTHER: Placebo

Sponsor

AstraZeneca